Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02983734
Other study ID # W81XWH-15-1-0588
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 2015
Est. completion date September 2019

Study information

Verified date January 2019
Source Boston University Charles River Campus
Contact Allison Coyne, B.S.
Phone 617-358-3048
Email afcoyne@bu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the efficacy of d-cycloserine (DCS) treatment for Gulf War Illness (GWI). Gulf War veterans with Gulf War Illness experience numerous chronic health symptoms, including cognition and fatigue, which reduces their quality of life. Gulf War veterans are in urgent need of novel treatment plans to tackle elusive symptomatology of Gulf War Illness. By using the literature of previous studies, the investigators have chosen to investigate d-cycloserine as a possible candidate for treating GWI, specifically cognitive symptoms. DCS has been shown to reduce neuroinflammation, regulate glutamate levels, and improve synaptic functioning in key areas of the brain.


Description:

Our study is a pilot study for the novel treatment of d-cycloserine to treat GWI. Our study will consist of two experimental groups of equal size (n=28): DCS treatment group and a placebo group. Participants will be randomized into either group; with a double blind study design. Participants will be instructed to self-administer their treatment pills once per day for 28 days. There will be a total of 6 study visits that will include medical and neuropsychological assessment. The first visit will be for establishing eligibility and baseline functioning. Three visits (visits 2-4) will occur during the medication trial (day 1, day 2 and two weeks into medication/placebo). Visit 5 will occur around the time medication/placebo is finished. Visit 6 (follow up) will occur one month after medication/placebo is complete.


Recruitment information / eligibility

Status Recruiting
Enrollment 56
Est. completion date September 2019
Est. primary completion date September 2019
Accepts healthy volunteers No
Gender All
Age group 43 Years to 85 Years
Eligibility Inclusion Criteria:

- Veterans of the 1991 Gulf War, male or female

- Physical examination and laboratory findings within normal limits

- Willingness and ability to participate in the informed consent process and comply with study protocols

- Symptom criteria: Meets Gulf War Illness criteria with the cognitive symptom domain being present. Veteran does not have medical exclusions for Gulf War Illness

Exclusion Criteria:

- Veteran lacks the capacity to provide consent during the informed consent process

- Veteran has the one of the following medical exclusion conditions and/or has been active or received treatment within the past 5 years: Cancer (except nonmelanoma skin cancer), diabetes (not well managed), seizure disorder, heart disease (except hypertension), liver disease, kidney disease, Lupus, multiple sclerosis, stroke, chronic infectious disease, immune disorder/immunosuppression

- Veteran has a history of a major psychiatric or central nervous system disorder that can affect cognitive function (ie. epilepsy, brain tumor, Parkinson's Disease)

- Veteran has been hospitalized in the past 5 years for depression, PTSD, alcohol or drug dependence

- Veteran has current suicidal ideation or current alcohol or drug dependence

- Pregnant women, lactating women, women who are breastfeeding, or women of childbearing potential who are not using medically accepted forms of contraception

- Veteran is active duty personnel

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
D-cycloserine
Partial agonist of N-methyl-D-aspartate (NMDA) receptor
Placebos
Sugar pill

Locations

Country Name City State
United States Boston University Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Boston University Charles River Campus

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neuropsychological Test Battery 8 weeks per subject
Secondary Symptom Questionnaires 8 weeks per subject
See also
  Status Clinical Trial Phase
Recruiting NCT04254627 - TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset Phase 1
Terminated NCT02011542 - Probiotic (VSL #3) for Gulf War Illness Phase 2/Phase 3
Recruiting NCT03078530 - Probiotic (Visbiome) for Gulf War Illness Phase 2/Phase 3
Recruiting NCT04058275 - "Immunomodulation in GWI (Phlebotomy)"
Recruiting NCT04255498 - Understanding GWI: Integrative Modeling Phase 1
Completed NCT02782780 - Cognitive Behavioral Therapy for Insomnia for Gulf War Illness N/A
Recruiting NCT05972291 - Mechanisms of Gulf War Illness N/A
Recruiting NCT04182659 - Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms N/A
Recruiting NCT04046536 - rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI) N/A
Recruiting NCT05377242 - Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI N/A
Recruiting NCT05675878 - Confirmation of Diet as a Treatment for Gulf War Illness Phase 3
Recruiting NCT05736146 - Validating Gulf War Illness Blood Biomarkers
Not yet recruiting NCT05820893 - Resistant Potato Starch to Alleviate GWI Phase 2
Terminated NCT01846182 - Research Examining Gulf War Illness in Our Nations Service Members Phase 2
Active, not recruiting NCT05252949 - OEA for Targeting Lipid Metabolism in GWI N/A
Completed NCT02378025 - Treating Chronic Pain in Gulf War Illness N/A
Completed NCT02865460 - Coenzyme Q10 Phase III Trial in Gulf War Illness Phase 3
Completed NCT02909686 - Effects of Botanical Microglia Modulators in Gulf War Illness N/A
Completed NCT01291758 - Exercise in Gulf War Illness (GWI)
Completed NCT01011348 - Q10 for Gulf War Veterans N/A